Low monoclonal antibody (mAb) titer is one of the most frustrating challenges in biopharmaceutical research and manufacturing. A process that once produced stable yields can suddenly become inconsistent, slowing development timelines and increasing production costs. In many cases, the issue does not begin at purification or downstream analysis. Instead, the problem often starts much earlier in...